Agomelatine - Nectid

Drug Profile

Agomelatine - Nectid

Alternative Names: NRT-31; NRT-34; NRT-36

Latest Information Update: 30 Jul 2015

Price : $50

At a glance

  • Originator Nectid
  • Class Acetamides; Antidepressants; Hypnosedatives; Sleep disorder therapies; Small molecules
  • Mechanism of Action Melatonin MT1 receptor agonists; Melatonin MT2 receptor agonists; Serotonin 2C receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Autistic disorder; Fibromyalgia; Multiple sclerosis; Neuropathic pain

Most Recent Events

  • 30 Jul 2015 No recent reports on development identified - Clinical-Phase-Unknown for Multiple sclerosis in USA (unspecified route)
  • 30 Jul 2015 No recent reports on development identified - Phase-II for Autistic disorder (In children) in USA (unspecified route)
  • 30 Jul 2015 No recent reports on development identified - Phase-II for Fibromyalgia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top